Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Core binding factor (CBF) AML (eg, inversion 16 and translocation 8;21) has generally been considered favorable risk although the 50% long-term survival demonstrates the need for better delineating high-risk subsets.

KIT Mutations Confer Worse Prognosis in Core Binding Factor Leukemias